Fertility sparing surgery in epithelial ovarian cancer in Italy: perceptions, practice, and main issues

A Bergamini, M Petrone, E Rabaiotti, F Pella, Raffaela Cioffi, EG Rossi, V Di Mattei, M Candiani, G Mangili

Research output: Contribution to journalArticle

Abstract

© 2017 Informa UK Limited, trading as Taylor & Francis Group About 2.7% of patients epithelial ovarian cancers (EOC) are younger than 40 and present with stage I disease. For this subset of women, the issue of fertility sparing surgery (FSS) has become critical. The aim of this survey was to investigate the management of EOC patients desiring to preserve fertility in Italy. A questionnaire consisting of 30 items was developed to evaluate: patient-selection criteria, rate of FSS, patient’s counseling- and pregnancy-timing, fertility preservation, obstetrics, and oncologic outcomes. One expert clinician for each of 50 major gynecologic oncology centers was invited to participate. Data were entered into a database and statistically analyzed. 74% of questionnaires were complete. The proportion of EOC patients treated with FSS was <10%, 10%–20% and > 20% in 70.3%, 24.3% and 5.4% of cases, respectively. Age, fertility preservation desire, histotype, and stage were considered relevant to select patients for a conservative treatment for 64.8%, 72.9%, and 78.3% of responders, respectively. Only 17 centers (45.9%) resulted to have an assisted reproductive technique service and Obstetrics Department. Our survey highlights discrepancies among oncologists in the management of patients with early EOC undergoing FSS. More efforts should be made to define and broadcast the best management before and after surgery. © 2017 Informa UK Limited, trading as Taylor & Francis Group
Original languageEnglish
Pages (from-to)305-308
Number of pages4
JournalGynecological Endocrinology
Volume34
Issue number4
DOIs
Publication statusPublished - 2018

Fingerprint

Italy
Fertility
Fertility Preservation
Patient Selection
Assisted Reproductive Techniques
Hospital Obstetrics and Gynecology Department
Birth Rate
Obstetrics
Ovarian epithelial cancer
Counseling
Databases
Pregnancy
Surveys and Questionnaires

Cite this

Fertility sparing surgery in epithelial ovarian cancer in Italy: perceptions, practice, and main issues. / Bergamini, A; Petrone, M; Rabaiotti, E; Pella, F; Cioffi, Raffaela; Rossi, EG; Di Mattei, V; Candiani, M; Mangili, G.

In: Gynecological Endocrinology, Vol. 34, No. 4, 2018, p. 305-308.

Research output: Contribution to journalArticle

Bergamini, A ; Petrone, M ; Rabaiotti, E ; Pella, F ; Cioffi, Raffaela ; Rossi, EG ; Di Mattei, V ; Candiani, M ; Mangili, G. / Fertility sparing surgery in epithelial ovarian cancer in Italy: perceptions, practice, and main issues. In: Gynecological Endocrinology. 2018 ; Vol. 34, No. 4. pp. 305-308.
@article{f673c35f513343ad927f2165882833f4,
title = "Fertility sparing surgery in epithelial ovarian cancer in Italy: perceptions, practice, and main issues",
abstract = "{\circledC} 2017 Informa UK Limited, trading as Taylor & Francis Group About 2.7{\%} of patients epithelial ovarian cancers (EOC) are younger than 40 and present with stage I disease. For this subset of women, the issue of fertility sparing surgery (FSS) has become critical. The aim of this survey was to investigate the management of EOC patients desiring to preserve fertility in Italy. A questionnaire consisting of 30 items was developed to evaluate: patient-selection criteria, rate of FSS, patient’s counseling- and pregnancy-timing, fertility preservation, obstetrics, and oncologic outcomes. One expert clinician for each of 50 major gynecologic oncology centers was invited to participate. Data were entered into a database and statistically analyzed. 74{\%} of questionnaires were complete. The proportion of EOC patients treated with FSS was <10{\%}, 10{\%}–20{\%} and > 20{\%} in 70.3{\%}, 24.3{\%} and 5.4{\%} of cases, respectively. Age, fertility preservation desire, histotype, and stage were considered relevant to select patients for a conservative treatment for 64.8{\%}, 72.9{\%}, and 78.3{\%} of responders, respectively. Only 17 centers (45.9{\%}) resulted to have an assisted reproductive technique service and Obstetrics Department. Our survey highlights discrepancies among oncologists in the management of patients with early EOC undergoing FSS. More efforts should be made to define and broadcast the best management before and after surgery. {\circledC} 2017 Informa UK Limited, trading as Taylor & Francis Group",
author = "A Bergamini and M Petrone and E Rabaiotti and F Pella and Raffaela Cioffi and EG Rossi and {Di Mattei}, V and M Candiani and G Mangili",
year = "2018",
doi = "10.1080/09513590.2017.1393508",
language = "English",
volume = "34",
pages = "305--308",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Fertility sparing surgery in epithelial ovarian cancer in Italy: perceptions, practice, and main issues

AU - Bergamini, A

AU - Petrone, M

AU - Rabaiotti, E

AU - Pella, F

AU - Cioffi, Raffaela

AU - Rossi, EG

AU - Di Mattei, V

AU - Candiani, M

AU - Mangili, G

PY - 2018

Y1 - 2018

N2 - © 2017 Informa UK Limited, trading as Taylor & Francis Group About 2.7% of patients epithelial ovarian cancers (EOC) are younger than 40 and present with stage I disease. For this subset of women, the issue of fertility sparing surgery (FSS) has become critical. The aim of this survey was to investigate the management of EOC patients desiring to preserve fertility in Italy. A questionnaire consisting of 30 items was developed to evaluate: patient-selection criteria, rate of FSS, patient’s counseling- and pregnancy-timing, fertility preservation, obstetrics, and oncologic outcomes. One expert clinician for each of 50 major gynecologic oncology centers was invited to participate. Data were entered into a database and statistically analyzed. 74% of questionnaires were complete. The proportion of EOC patients treated with FSS was <10%, 10%–20% and > 20% in 70.3%, 24.3% and 5.4% of cases, respectively. Age, fertility preservation desire, histotype, and stage were considered relevant to select patients for a conservative treatment for 64.8%, 72.9%, and 78.3% of responders, respectively. Only 17 centers (45.9%) resulted to have an assisted reproductive technique service and Obstetrics Department. Our survey highlights discrepancies among oncologists in the management of patients with early EOC undergoing FSS. More efforts should be made to define and broadcast the best management before and after surgery. © 2017 Informa UK Limited, trading as Taylor & Francis Group

AB - © 2017 Informa UK Limited, trading as Taylor & Francis Group About 2.7% of patients epithelial ovarian cancers (EOC) are younger than 40 and present with stage I disease. For this subset of women, the issue of fertility sparing surgery (FSS) has become critical. The aim of this survey was to investigate the management of EOC patients desiring to preserve fertility in Italy. A questionnaire consisting of 30 items was developed to evaluate: patient-selection criteria, rate of FSS, patient’s counseling- and pregnancy-timing, fertility preservation, obstetrics, and oncologic outcomes. One expert clinician for each of 50 major gynecologic oncology centers was invited to participate. Data were entered into a database and statistically analyzed. 74% of questionnaires were complete. The proportion of EOC patients treated with FSS was <10%, 10%–20% and > 20% in 70.3%, 24.3% and 5.4% of cases, respectively. Age, fertility preservation desire, histotype, and stage were considered relevant to select patients for a conservative treatment for 64.8%, 72.9%, and 78.3% of responders, respectively. Only 17 centers (45.9%) resulted to have an assisted reproductive technique service and Obstetrics Department. Our survey highlights discrepancies among oncologists in the management of patients with early EOC undergoing FSS. More efforts should be made to define and broadcast the best management before and after surgery. © 2017 Informa UK Limited, trading as Taylor & Francis Group

U2 - 10.1080/09513590.2017.1393508

DO - 10.1080/09513590.2017.1393508

M3 - Article

VL - 34

SP - 305

EP - 308

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 4

ER -